Santen Ventures
6401 Hollis Street, Suite 125, Emeryville, California, 94608, United States
Overview
Santen Ventures is a wholly-owned subsidiary of Santen Holdings. They invest in promising seed-stage firms developing innovative technology.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- BELKIN Vision
Led · Series B · Jul 2020
Belkin Laser develops an automated, non-contact, painless laser treatment for glaucoma that is activated by a touchscreen and controlled by a high-resolution image acquisition algorithm and a proprietary eye tracker. The technology, originated by Prof. Michael Belkin and led by CEO Daria Lemann-Blumenthal, is designed to be used by all ophthalmologists to increase treated patient volumes in both central and rural areas and to open a new revenue stream for clinics and hospitals. The company closed a $12.25M Series B and intends to use the funds to continue GLAUrious, its multi-center trial in Europe, and to initiate trials in Asia. Prior to the Series B, Belkin had raised $6.6M, which included an Israel Innovation Authority incubator grant at the Rad Biomed Accelerator and a $3M European Horizon 2020 grant. The company also raised an additional $2.5M as part of a Series A financing led by ZIG Ventures from Singapore. No operational metrics or valuation were disclosed in the article.
- Qura
Led · Series A · Jul 2018
Qura, Inc. has developed the QSmart™ System, a wireless, implantable pressure sensor and monitoring system designed to continuously detect and track intraocular pressure (IOP). The micro-sized, programmable sensor collects continuous IOP data and delivers it to desktop, handheld or tablet devices so physicians can evaluate treatment effectiveness in real time. Qura positions the system to facilitate timely and targeted medical or surgical intervention for glaucoma patients worldwide, noting approximately 80 million people are affected by glaucoma. The company announced a $1 million strategic investment from Santen Ventures to support development and commercialization as part of its Series A financing. The QSmart™ System is currently in the pre-clinical stage of development. InFocus Capital Partners initiated and sponsored the Series A round. Qura Inc. develops QSmart, a wireless implantable pressure sensor technology and monitoring system aimed at improving medical and surgical management of glaucoma. QSmart is a micro-sized, wireless implantable sensor that can be programmed to physicians' specifications to monitor 24/7 intraocular pressure (IOP), detect pressure events and provide real-time IOP updates. The system delivers collected IOP data to a handheld device or tablet so physicians can evaluate treatment effectiveness in real time. Qura is led by Douglas Adams, President and Co-founder. The company raised a Series A round of undisclosed size from InFocus Capital Partners and intends to use the funds to continue to advance its system.
Team
No current team members are available.